SG Americas Securities LLC Has $1.29 Million Holdings in Celldex Therapeutics, Inc. $CLDX

SG Americas Securities LLC grew its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 143.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 47,340 shares of the biopharmaceutical company’s stock after purchasing an additional 27,872 shares during the period. SG Americas Securities LLC owned approximately 0.07% of Celldex Therapeutics worth $1,286,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the company. Russell Investments Group Ltd. lifted its holdings in shares of Celldex Therapeutics by 27.6% in the second quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock valued at $47,000 after purchasing an additional 501 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Celldex Therapeutics by 1.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,451 shares of the biopharmaceutical company’s stock valued at $798,000 after purchasing an additional 680 shares in the last quarter. DNB Asset Management AS lifted its holdings in shares of Celldex Therapeutics by 7.7% in the third quarter. DNB Asset Management AS now owns 13,251 shares of the biopharmaceutical company’s stock valued at $343,000 after purchasing an additional 951 shares in the last quarter. Aster Capital Management DIFC Ltd bought a new stake in shares of Celldex Therapeutics in the third quarter valued at about $26,000. Finally, Wilmington Savings Fund Society FSB bought a new stake in shares of Celldex Therapeutics in the third quarter valued at about $42,000.

Celldex Therapeutics Stock Performance

NASDAQ:CLDX opened at $31.35 on Wednesday. The stock’s 50-day simple moving average is $27.89 and its 200 day simple moving average is $26.85. The company has a market cap of $2.09 billion, a P/E ratio of -8.06 and a beta of 1.19. Celldex Therapeutics, Inc. has a 52-week low of $14.40 and a 52-week high of $34.52.

Celldex Therapeutics (NASDAQ:CLDX) last released its earnings results on Wednesday, February 25th. The biopharmaceutical company reported ($1.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.00) by ($0.22). The company had revenue of $0.12 million during the quarter, compared to analyst estimates of $1.53 million. As a group, equities analysts predict that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently commented on the company. Wolfe Research upgraded Celldex Therapeutics from a “peer perform” rating to an “outperform” rating and set a $44.00 price target on the stock in a report on Monday, March 23rd. Barclays boosted their price target on Celldex Therapeutics from $21.00 to $24.00 and gave the company an “underweight” rating in a report on Wednesday, December 17th. Stifel Nicolaus restated a “buy” rating and issued a $68.00 price target (up from $58.00) on shares of Celldex Therapeutics in a report on Thursday, February 26th. The Goldman Sachs Group boosted their price target on Celldex Therapeutics from $30.00 to $34.00 and gave the company a “neutral” rating in a report on Monday, March 2nd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Celldex Therapeutics in a research report on Wednesday, January 21st. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $44.45.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.